2014

Considering Corticosteroid Nasal Sprays

Leading patient advocacy group asks FDA to maintain prescription status

MCLEAN, Va., July 31, 2013 /PRNewswire-USNewswire/ -- Today, leading nonprofit patient advocacy and education organization Allergy & Asthma Network Mothers of Asthmatics (AANMA) released results of a survey regarding patient use of intranasal corticosteroid sprays. Findings were shared during the Food and Drug Administration (FDA) Nonprescription Drug Advisory Committee meeting considering the switch of triamcinolone nasal spray from prescription to over-the-counter status.

"AANMA conducted a survey of more than 1,600 families and patients who use nasal corticosteroid sprays and found that they are prescribed to treat a complex set of symptoms for patients who often take an assortment of other medications," says Nancy Sander, president and founder of AANMA and a nationally recognized patient advocate. "This makes patient education a high priority for safe use. When medications are available over-the-counter, families tell us they assume it is safe to self-diagnose their conditions and pick and choose among medications."

Nine out of 10 said they prefer to rely on medical professionals to diagnose and manage their conditions. When asked if intranasal corticosteroid sprays should be available without a prescription, the overwhelming concerns expressed were about cost: 72 percent felt moving the medication OTC would increase their financial burden.

"The truth is," Sander continues, "the average patient doesn't know allergic from non-allergic rhinitis, or boggy nasal passages from sinus infections or a deviated septum. These are complex conditions, and intranasal corticosteroids are serious medications with the potential for unwanted side effects. Patients deserve the best possible care and guidance from their physicians; they should not be left on their own to self-diagnose at the pharmacy."

AANMA has identified seven important facts patients should understand regarding the efficient and safe use of intranasal corticosteroid sprays:

  1. Why the medication was prescribed
  2. How quickly to expect improvement in symptoms 
  3. What to do if symptoms don't respond as expected
  4. How to aim the nasal spray tip to deliver medication to the right part of the nose and avoid septal irritation, nose bleeds or damage
  5. How often to visit the doctor to have your nose re-examined and the treatment plan adjusted
  6. The possible role of environmental allergens and how reducing exposure at home, school, work or play could reduce symptoms
  7. The importance of a yearly eye exam and reporting all medications, including intranasal and other corticosteroids, to the ophthalmologist

Currently this information is relayed to patients by healthcare professionals, but if these medications were to be available without a prescription and patient education, the details would need to be communicated fully and clearly.

Find out more about the nasal sprays at http://www.aanma.org/2010/06/nasal-allergies-sniff-this/

ABOUT AANMA
Allergy & Asthma Network Mothers of Asthmatics (AANMA) is the leading national nonprofit organization dedicated to ending needless death and suffering due to asthma, allergies and related conditions. AANMA specializes in sharing family-friendly, medically accurate information through its award-winning publications Allergy & Asthma Today magazine and The MA Report newsletter, its web site at www.aanma.org and numerous community outreach programs. Follow AANMA on Facebook at facebook.com/AANMA and on Twitter at twitter.com/AANMA.

Contact: Gary Fitzgerald
Allergy & Asthma Network
Mothers of Asthmatics
703-641-9595
gfitzgerald@aanma.org

SOURCE Allergy & Asthma Network Mothers of Asthmatics



RELATED LINKS
http://www.aanma.org

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.